Lung Cancer - Bayer
Lung Cancer - Bayer supports education for healthcare professionals, patients, and caregivers on HER2-mutated lung cancer, biomarker testing, and personalized treatment to improve patient care.
Browse similar grants
Funder: Bayer
Due Dates: At least 45 days before the event (complete application) | Monthly (review of complete proposals)
Funding Amounts: Educational grant support restricted to the purpose designated in the proposal
Summary: Supports education on HER2-mutated non-small cell lung cancer, including biomarker testing, personalized treatment, and supportive care.
Key Information: Individuals and group practices are ineligible; CE/CME submissions must comply with ACCME guidelines.
Description
Bayer’s Oncology Medical Affairs Department supports educational programs addressing non-small cell lung cancer (adenocarcinoma), with particular emphasis on activating HER2 mutations as actionable biomarkers. Intended audiences include oncologists, community healthcare professionals, oncology advanced practice providers, patients, and caregivers. Educational priorities include tissue and circulating tumor DNA liquid-biopsy testing, interpretation of HER2 biomarker results, and patient understanding of testing and treatment goals.
Programs may also address evolving treatment options, differences between those options, and personalized care plans for HER2-mutated disease. Bayer’s interests extend to optimizing the patient experience through better patient–care-team communication, overcoming barriers to continuity of care, monitoring and managing treatment-related toxicities, supportive care, and adherence counseling.
